online game drawing
Brentford boss Thomas Frank claimed Brighton forward Joao Pedro should have been sent off during his side’s goalless Premier League draw at the Amex Stadium. Pedro escaped punishment after swinging an arm at Bees substitute substitute Yehor Yarmoliuk without making contact. VAR reviewed the second-half incident but deemed there was no violent conduct. Frank and Brighton head coach Fabian Hurzeler disagreed about the decision. “As I understand the rules, you can’t swing your arm to try to hit someone,” said Frank. “If you hit them or not, it’s a red, that’s the way I understand the rules.” Frank spoke to the match officials, including referee Andy Madley, about the flashpoint at full-time. “They haven’t seen the situation yet, not on TV afterwards,” said Frank. “To be fair to him, I think the angle can be tricky so that’s why you’ve got VAR.” Asked about Frank’s assessment, Hurzeler replied: “Interesting opinion. I see it completely different. “For me, it’s not a red card. He tried to get free from a person.” Brighton were booed off after their winless run was stretched to six top-flight games. Albion dominated for large periods and hit the woodwork inside four minutes through Julio Enciso. Bees goalkeeper Mark Flekken made some important saves before being forced off injured in the 36th minute, albeit his replacement Hakon Valdimarsson was rarely tested on his Premier League debut. The Seagulls remain 10th ahead of Monday’s trip to Aston Villa, with Brentford a position and two points below moving towards their New Year’s Day showdown with Arsenal. Hurzeler thought the jeers at full-time were unfair. “The team doesn’t deserve that because in all the games we had in the last weeks they were all good, they were all intense, they were all where we thought we deserved more” said the German, whose team have lost to Fulham and Crystal Palace and drawn with Southampton, Leicester and West Ham in recent matches. “We try to work hard to satisfy our supporters, we try to give them what they deserve, we try to make them proud. “But the Premier League is tough. We know there will be (tough) periods we have to go through, especially with this young squad. “We try to stick together, find the positive and keep on going.” Brentford, who remain without a top-flight away win this term, had an early Yoane Wissa finish ruled out for offside following VAR intervention but barely threatened, despite an improved second-half showing. Frank, who is awaiting news on Flekken and defender Ben Mee, who also left the field injured, said: “I thought it was a fair point. “Brighton were better in the first half, no big, clearcut chances, and I thought we were better second half. “Overall, I’m happy with the performance, especially the way we defended. “We haven’t had too many clean sheets this season, so in that context I thought it was very impressive against a good Brighton team. “We know we have a lot of players out – we get two more injuries during the game. “The way the players showed their mentality and character and dug in was hugely impressive.”
COLUMBUS, Ohio — Will Howard passed for two touchdowns and rushed for another, TreVeyon Henderson ran for a score and No. 2 Ohio State beat previously undefeated No. 5 Indiana 38-15 on Saturday. All Ohio State (10-1, 7-1 Big Ten) has to do now is beat Michigan at home next Saturday and it will earn a return to the Big Ten championship game for the first time since 2020 and get a rematch with No. 1 Oregon. The Ducks beat Ohio State 32-31 in a wild one back on Oct. 12. The Hoosiers (10-1, 7-1) had their best chance to beat the Buckeyes for the first time since 1988 but were hurt by special teams mistakes and disrupted by an Ohio State defense that sacked quarterback Kurtis Rourke five times. “In life, all good things come to an end,” Indiana coach Curt Cignetti said. Late in the first half, Indiana punter James Evans fumbled a snap and was buried at his own 7-yardline with the Buckeyes taking over. That turned quickly into a 4-yard TD run by Henderson that gave the Buckeyes a 14-7 lead. Early in the second half, Caleb Downs fielded an Evans punt at the Ohio State 21, raced down the right sideline, cut to the middle and outran the coverage for a touchdown that put the Buckeyes up 21-7. It was the first time a Buckeye returned a punt for a touchdown since 2014. Howard finished 22-for-26 passing for 201 yards. Emeka Egbuka had seven catches for 80 yards and a TD. “Our guys just played with a chip today, and that’s the way you got to play the game of football,” Ohio State coach Ryan Day said. Indiana scored on its first possession of the game and its last, both short runs by Ty Son Lawson, who paced the Hoosiers with 79 rushing yards. Rourke was 8-for-18 passing for 68 yards. “We had communication errors, pass (protection), every time we dropped back to pass, something bad happened,” Cignetti said. Indiana’s 151 total yards was its lowest of the season. And it was the most points surrendered by the Hoosier’s defense. The Hooseries’ special season was blemished by the Buckeyes, who beat Indiana for the 30th straight time. The Hoosiers were eyeing its first conference crown since sharing one with two other teams in 1967. That won’t happen now. “Ohio State deserved to win,” Cignetti said. “They had those (third quarter scores), and we just couldn’t respond.” Ohio State didn’t waste the opportunities presented by the Hoosiers when they got sloppy. The Buckeyes led 14-7 at the break and took control in the second half. An offensive line patched together because of multiple injuries performed surprisingly well. “We know what was at stake,” Day said. “We don’t win this game, and we have no chance to go to Indianapolis and play in the Big Ten championship. And that’s real. We’ve had that approach for the last few weeks now, more than that.”NorthView Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Filing of ...
NASA Leadership to Visit, Strengthen Cooperation with MexicoMIAMI GARDENS, Fla. – Another week, another pair of records for Miami quarterback Cam Ward — breaking 40-year-old marks by Bernie Kosar in both cases. Ward, Miami's Heisman Trophy contender who already holds the Hurricanes' single-season record for touchdown passes and is on pace to break the school mark for completion percentage, on Saturday eclipsed Kosar's school records for both passing yards in a season and completions in a season. Recommended Videos Ward's 13-yard completion to Damien Martinez with 1:27 left in the second quarter gave him 3,643 yards for the season. Kosar's mark of 3,642 yards was set in 1984. Later Saturday, Ward threw a 15-yard pass to Xavier Restrepo for his 263rd completion of the year — topping Kosar's mark of 262, also set in 1984. “Congrats #CamWard,” Kosar posted on social media. “U R Awesome.” Ward is on pace to break Miami's single-season completion percentage mark of 65.8% set last year by Tyler Van Dyke. He also is on pace to top the Miami career mark — among those with at least 300 attempts — of 64.3% set by D'Eriq King in 2020 and 2021. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-footballClick celebrates significant growth milestones while introducing a new initiative to support and empower photojournalists in sharing authentic, impactful stories through the platform. SAN FRANCISCO , Dec. 11, 2024 /PRNewswire/ -- Click , a groundbreaking mobile app that fights misinformation by making it simple to capture and publish authenticated content, powered by the Nodle Network , has recently launched the Click Photojournalism Fellowship, to empower photojournalists to join Click's mission to build a more truthful future. Joining the fellowship will give photojournalists exposure of their work via the Click app and Nodle Network and allow each photojournalist to share their stories and their photos. Additionally, Click has just reached two growth milestones in its first year of operation, passing 50,000 users and over 1,000 new photos authenticated by Click daily. These follow Click's public beta launch in March. The Click camera app is currently available for download on both iOS or Android , and all content captured with Click can be accessed through the app and on Click's website at clickapp.com . The first two photojournalists to join the Click Fellowship are: Patricia Chaira , based in Beirut, Lebanon . Patricia had been on the ground in Beirut capturing the conflict as it's happening on Click. Patricia's story and photos can be seen here . Bill Finan , based in Rochester, New York . Bill is working at the limits of art, exploration and photojournalism, becoming famous in the underground world of Urban Exploring or "URBEX". Bill's story and photos can be seen here . "We're thrilled to collaborate with photojournalists, empowering them to share their authentic stories through Click. In an era where digital content authenticity is crucial, we're leveraging blockchain to support journalists in building transparency and trust. The Click Photojournalism Fellowship sets a new standard for credibility in journalistic content on social media," says Micha Benoliel , CEO and co-founder of Intergalactic Labs, the team behind Click and Nodle. Click aims to grow the fellowship to over 20 photojournalists in early 2025 and is currently seeking more photojournalist partners. Photojournalists who join the program will share their recent work via Click's blog (both Click and non-Click photos), that represent their photojournalistic perspective, share their journalist story and be promoted across the Click and Nodle communities. Journalists will also provide feedback on the Click app periodically via scheduled sessions with Click's team. To apply and join the fellowship, photojournalists can fill out this short application and share samples of their work. About Click: Click is a new mobile app empowering everyone to easily create authentic media content. Click is on a mission to combat misinformation and bring truthful photos and videos aka "Deep Reals" to everyone via immutable digital proofs of authenticity. With Click, you can confirm content is real and happened at a specific location, time and via a specific mobile device and camera. This is all made possible by ContentSign , Click's proprietary technology which proves the integrity of data from its moment of capture on-chain. Click is built on ZKsync , the leading Ethereum Layer 2 blockchain and is powered by the Nodle DePIN. Click supports the Coalition for Content Provenance and Authenticity (C2PA) and is a member of the Adobe-led Content Authenticity Initiative (CAI). Download Click on iOS or Android and visit us at clickapp.com to learn more and see recent press coverage. View original content to download multimedia: https://www.prnewswire.com/news-releases/click-camera-app-announces-new-photojournalism-fellowship-as-app-reaches-50-000-users-signing-1-000-authenticated-photos-daily-302329583.html SOURCE Nodle © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Global Launch of JETOUR T2 i-DM: Reshaping the Hybrid SUV MarketLOS ANGELES (AP) — Hannah Hidalgo scored 24 points and No. 6 Notre Dame defeated JuJu Watkins and third-ranked Southern California 74-61 on Saturday in a marquee matchup on the West Coast. Watkins and the Trojans (4-1) fell behind early and were down 21 points in the fourth quarter. She had 24 points, six rebounds and five assists. Hidalgo came out shooting well, hitting 5 of 8 from the floor in the first quarter and had 16 points at the break. She added six rebounds and eight assists. Hidalgo's backcourt mate, Olivia Miles, added 20 points, eight rebounds and seven assists for the Fighting Irish (5-0). Even though Hidalgo outshone her, Watkins’ imprint was all over the game. A documentary about her life aired on NBC leading into the nationally televised game. A buzz arose when Snoop Dogg walked in shortly before tipoff wearing a jacket in USC colors with Watkins' name and number on the front and back. Her sister, Mali, sang the national anthem. Notre Dame: The Irish struck quickly, racing to a 20-10 lead in the opening quarter. Even after cooling off a bit, they never trailed and stayed poised when the Trojans got within three in the second and third quarters. USC: The Trojans were without starting guard Kennedy Smith, whose defense on Hidalgo would have proven valuable. It was announced shortly before tipoff that she had a surgical procedure and will return at some point this season. The Trojans got within three points three times but the Irish remained poised and never gave up the lead. Notre Dame's defense forced the Trojans into 21 turnovers, which led to 22 points for the Irish. Watkins, Kaleigh Heckel and Talia von Oelhoffen had five each. USC was just 1 of 13 from 3-point range Notre Dame plays TCU on Nov. 29 in the Cayman Islands Classic. USC plays Seton Hall in the Women's Acrisure Holiday Invitational on Nov. 27 in Palm Desert, California. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here. AP women’s college basketball: https://apnews.com/hub/ap-top-25-womens-college-basketball-poll and https://apnews.com/hub/womens-college-basketball
Vikings vs Bears Prediction: Odds, Expert Picks, QB Matchup, Injury News, Betting Trends and Stats, /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended . "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. As of , the Company had in cash and cash equivalents. As of , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on . During the year ended , the Company received net proceeds of from the issuance of equity. The Company expects to raise additional capital to support operations. R&D expenses were for the full year ended , compared to for the full year ended . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. G&A expenses were for the full year ended , compared to for the full year ended . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. For the full year ended , stock-based compensation expense was as compared to for the prior year. The increase of is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was during the year ended , compared to for the year ended , as the plan was initiated in . For the years ended and 2023, stock-based compensation expense also includes and , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss was , or per share for the year ended , compared to a net loss of , or per share for the year ended , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of offset by a decrease of in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit . This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at , including in Citius Pharma's Annual Report on Form 10-K for the year ended , filed with the SEC on , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. 908-967-6677 x113 STiR-communications -- Financial Tables Follow –The rapper Sean "Diddy" Combs and the suspected health care CEO assassin Luigi Mangione have decided on a similar defense strategy: Hire an Agnifilo. Or two. Marc Agnifilo is heading Combs' defense against racketeering conspiracy and sex trafficking charges , while Karen Friedman Agnifilo is leading Mangione's murder defense , with Marc in a support role. For much of the past few decades, the legal power couple often found themselves on opposite sides of such complex cases – she for the prosecution, and he for the defense. Now, they find themselves representing two of the most high-profile cases in the country today. From 2014 to 2021, Karen was the second-in-command in the Manhattan District Attorney's Office, which brought notable cases against defendants including Harvey Weinstein and Allen Weisselberg, the chief financial officer of the Trump Organization. She left the department in 2021 and has since moved into media, with a stint as a CNN legal analyst and contributor. Marc, meanwhile, has represented many of the targets of those DA investigations, including "pharma bro" Martin Shkreli, Nxivm founder Keith Raniere and former Goldman Sachs banker Roger Ng. He worked for the law firm Brafman & Associates from 2006 until earlier this year, when he split off to co-found the firm Agnifilo Intrater . Parents to three adult children, the law is what brought them together. The two met at the Manhattan DA's office in 1992 while working on a case in which two bagel store deliverymen got into an argument, and one cut off the other's arm with a machete, according to The New York Times . Their intersecting careers have at times led to legal conflicts of interest. In 2011, Karen had to recuse herself from the Manhattan DA's case against Dominique Strauss-Kahn when the former head of the International Monetary Fund hired the law firm where Marc worked. "It's never been awkward," Marc told The New York Times in 2011. "We're pretty regimented about it. If she's recused from a case, we really don't talk about it." The Agnifilos declined a CNN request for an interview. But that was then, and now, the Agnifilos have joined forces. Monday, when Mangione appeared in a New York courthouse for his arraignment, Karen was positioned to his left, and Marc sat on his right. Karen spoke to the court and criticized what she called the NYPD's over-the-top "perp walk" of her client, drawing on her years of service for perspective. "He was on display for everyone to see in the biggest staged perp walk I've ever seen in my career," she said. Karen Friedman Agnifilo has decades of experience in the legal field, primarily in the Manhattan DA's Office. She most recently served as the chief assistant district attorney under then-District Attorney Cyrus Vance Jr. until 2021. Her professional bio notes her "critical leadership role in prosecuting high-profile violent crime cases, including complex cases involving a mental health component." She managed a team of 1,500 people with a $120 million budget and "was also integral to creating the office's Human Trafficking Unit, Hate Crimes Unit, Antiquities Trafficking Unit, Terrorism Unit, its Cybercrimes and Identity Theft Bureau, as well as working on the creation of Manhattan's first Mental Health Court," according to her bio. She left public service in 2021 – complete with a bagpipe sendoff from the NYPD and DA's office – and moved to private practice. In an interview with the " Shut Up Mommy's Talking " podcast in 2022, Karen said moving into defense work was an adjustment. She cited her husband's experience in deciding whom to take on as a client. "My husband's also a criminal defense attorney and he's had some clients who just aren't nice to him. And I don't mean, like just not a little bit nice, I mean like abusive," she said. "And I don't want that at this stage in my life." "There's no crime necessarily that I wouldn't take or even set of factors that I wouldn't take," she added. "I do believe that everyone's entitled to a defense and to good representation, and I've always believed that." Karen said she has also been influenced by her children. Her twin daughters took an interest in politics and the Black Lives Matter movement during the COVID-19 pandemic, changing her thinking on the topic. "I have to credit them with opening my eyes to these issues," she said. Her third child has autism, she told the podcast, and she had frustrating experiences trying to get them help. She then used her experiences as a "special needs mom" to implement systems in the DA's office to help those with less money or opportunity, she said. "That became sort of my mission at the DA's office. It was very much into alternatives to incarceration, I pushed that very hard," she said. In recent years, Karen has moved into the media. She has served as the legal adviser to the long-running show "Law & Order," worked as a CNN legal analyst and opines on legal issues as the podcast host of "Legal AF" and "MissTrial" on the MeidasTouch Network. Her vocal media presence may offer a preview of her defense strategy. Earlier this month on CNN, before taking on Mangione as a client, she offered her thoughts on how the case could proceed. "It looks to me like there might be a not guilty by reason of insanity defense that they're going to be thinking about because the evidence is going to be so overwhelming that he did what he did," she said on December 10 . "As a former prosecutor in that office, I would be concerned that you have someone who is a valedictorian of his class, he was brilliant his whole life, he comes from this great family. I mean, something changed, significantly, something changed. And they're going to potentially have a not guilty by reason of insanity potential defense, so the prosecutors are going to try to shore that up as well in their investigation." Marc Agnifilo similarly began his career in prosecutors' offices and has since made a mark defending high-profile defendants in complex cases on the state, federal and international levels. A graduate of Connecticut College and Brooklyn Law School, he worked at the US Attorney's Office for the District of New Jersey and as a Manhattan assistant district attorney before turning to criminal defense, his website states . He has defended some of the most publicly reviled defendants of the past decade in Shkreli and Raniere, both of whom were convicted at trial. "You may find him repulsive, disgusting and offensive. We don't convict people in this country for being repulsive or offensive," he argued in Raniere's trial on charges of racketeering and sex trafficking. "Unpopular ideas aren't criminal. Disgusting ideas aren't criminal." In recent months, Marc took on Combs' case and has repeatedly asked the court to release the rapper on bond before trial. Other cases, many of which are listed on his website, have been resolved without charges or with short sentences. He told Law.com earlier this year his new law firm will focus on complex criminal litigation with an eye toward trying cases. "I have found that people come to me when they have something to say against the government's allegations," Marc said. "Very often that means they want to go to trial. So we all plan to do what we've always done: to try a bunch of cases. That's our supreme value."
The rapper Sean "Diddy" Combs and the suspected health care CEO assassin Luigi Mangione have decided on a similar defense strategy: Hire an Agnifilo. Or two. Marc Agnifilo is heading Combs' defense against racketeering conspiracy and sex trafficking charges , while Karen Friedman Agnifilo is leading Mangione's murder defense , with Marc in a support role. For much of the past few decades, the legal power couple often found themselves on opposite sides of such complex cases – she for the prosecution, and he for the defense. Now, they find themselves representing two of the most high-profile cases in the country today. From 2014 to 2021, Karen was the second-in-command in the Manhattan District Attorney's Office, which brought notable cases against defendants including Harvey Weinstein and Allen Weisselberg, the chief financial officer of the Trump Organization. She left the department in 2021 and has since moved into media, with a stint as a CNN legal analyst and contributor. Marc, meanwhile, has represented many of the targets of those DA investigations, including "pharma bro" Martin Shkreli, Nxivm founder Keith Raniere and former Goldman Sachs banker Roger Ng. He worked for the law firm Brafman & Associates from 2006 until earlier this year, when he split off to co-found the firm Agnifilo Intrater . Parents to three adult children, the law is what brought them together. The two met at the Manhattan DA's office in 1992 while working on a case in which two bagel store deliverymen got into an argument, and one cut off the other's arm with a machete, according to The New York Times . Their intersecting careers have at times led to legal conflicts of interest. In 2011, Karen had to recuse herself from the Manhattan DA's case against Dominique Strauss-Kahn when the former head of the International Monetary Fund hired the law firm where Marc worked. "It's never been awkward," Marc told The New York Times in 2011. "We're pretty regimented about it. If she's recused from a case, we really don't talk about it." The Agnifilos declined a CNN request for an interview. But that was then, and now, the Agnifilos have joined forces. Monday, when Mangione appeared in a New York courthouse for his arraignment, Karen was positioned to his left, and Marc sat on his right. Karen spoke to the court and criticized what she called the NYPD's over-the-top "perp walk" of her client, drawing on her years of service for perspective. "He was on display for everyone to see in the biggest staged perp walk I've ever seen in my career," she said. From public service to defense Karen Friedman Agnifilo has decades of experience in the legal field, primarily in the Manhattan DA's Office. She most recently served as the chief assistant district attorney under then-District Attorney Cyrus Vance Jr. until 2021. Her professional bio notes her "critical leadership role in prosecuting high-profile violent crime cases, including complex cases involving a mental health component." She managed a team of 1,500 people with a $120 million budget and "was also integral to creating the office's Human Trafficking Unit, Hate Crimes Unit, Antiquities Trafficking Unit, Terrorism Unit, its Cybercrimes and Identity Theft Bureau, as well as working on the creation of Manhattan's first Mental Health Court," according to her bio. She left public service in 2021 – complete with a bagpipe sendoff from the NYPD and DA's office – and moved to private practice. In an interview with the " Shut Up Mommy's Talking " podcast in 2022, Karen said moving into defense work was an adjustment. She cited her husband's experience in deciding whom to take on as a client. "My husband's also a criminal defense attorney and he's had some clients who just aren't nice to him. And I don't mean, like just not a little bit nice, I mean like abusive," she said. "And I don't want that at this stage in my life." "There's no crime necessarily that I wouldn't take or even set of factors that I wouldn't take," she added. "I do believe that everyone's entitled to a defense and to good representation, and I've always believed that." Karen said she has also been influenced by her children. Her twin daughters took an interest in politics and the Black Lives Matter movement during the COVID-19 pandemic, changing her thinking on the topic. "I have to credit them with opening my eyes to these issues," she said. Her third child has autism, she told the podcast, and she had frustrating experiences trying to get them help. She then used her experiences as a "special needs mom" to implement systems in the DA's office to help those with less money or opportunity, she said. "That became sort of my mission at the DA's office. It was very much into alternatives to incarceration, I pushed that very hard," she said. In recent years, Karen has moved into the media. She has served as the legal adviser to the long-running show "Law & Order," worked as a CNN legal analyst and opines on legal issues as the podcast host of "Legal AF" and "MissTrial" on the MeidasTouch Network. Her vocal media presence may offer a preview of her defense strategy. Earlier this month on CNN, before taking on Mangione as a client, she offered her thoughts on how the case could proceed. "It looks to me like there might be a not guilty by reason of insanity defense that they're going to be thinking about because the evidence is going to be so overwhelming that he did what he did," she said on December 10 . "As a former prosecutor in that office, I would be concerned that you have someone who is a valedictorian of his class, he was brilliant his whole life, he comes from this great family. I mean, something changed, significantly, something changed. And they're going to potentially have a not guilty by reason of insanity potential defense, so the prosecutors are going to try to shore that up as well in their investigation." Marc has repped Shkreli, Diddy Marc Agnifilo similarly began his career in prosecutors' offices and has since made a mark defending high-profile defendants in complex cases on the state, federal and international levels. A graduate of Connecticut College and Brooklyn Law School, he worked at the US Attorney's Office for the District of New Jersey and as a Manhattan assistant district attorney before turning to criminal defense, his website states . He has defended some of the most publicly reviled defendants of the past decade in Shkreli and Raniere, both of whom were convicted at trial. "You may find him repulsive, disgusting and offensive. We don't convict people in this country for being repulsive or offensive," he argued in Raniere's trial on charges of racketeering and sex trafficking. "Unpopular ideas aren't criminal. Disgusting ideas aren't criminal." In recent months, Marc took on Combs' case and has repeatedly asked the court to release the rapper on bond before trial. Other cases, many of which are listed on his website, have been resolved without charges or with short sentences. He told Law.com earlier this year his new law firm will focus on complex criminal litigation with an eye toward trying cases. "I have found that people come to me when they have something to say against the government's allegations," Marc said. "Very often that means they want to go to trial. So we all plan to do what we've always done: to try a bunch of cases. That's our supreme value."Raiders' Antonio Pierce keeps it all the way real while discussing the Derek Carr revenge game that was supposed to happen'Wee Gav' inspired Hibs to defeat Hearts - the story of bad jokes, dancing and team spirit
Jenn Tran and Sasha Farber spark new frenzy with ‘good time’ social media postContrary to predictions, Yogi surpassed all expectations and led the BJP to an overwhelming win, effectively crushing the Samajwadi Party's (SP) hopes of a resurgence. The latest UP bypoll election results have brought out two significant messages that highlight why it is still nearly impossible for opposition parties to halt the triumph of the Bharatiya Janata Party (BJP). BJP has achieved its most remarkable performance yet in Maharashtra, paving the way for the formation of a government with a substantial majority, under the Mahayuti alliance. This is seen as a significant political win for the party, which is now in a stronger position to govern the state. In today's episode of DNA, Zee News explains, how BJP managed to win highest number of seats through its key agendas. Yogi Adityanath’s Victory in Uttar Pradesh By-Elections In Uttar Pradesh, Chief Minister Yogi Adityanath emerged victorious in the by-elections, a major test for his leadership. Contrary to predictions, Yogi surpassed all expectations and led the BJP to an overwhelming win, effectively crushing the Samajwadi Party's (SP) hopes of a resurgence. The victory was a testament to how the ideological appeal of Hindutva reached deep into the hearts of the electorate. Yogi Adityanath’s Win is a Triumph of Hindutva Yogi's success in the Uttar Pradesh by-elections is not just a win for the BJP; it is a victory for Hindutva, the ideological pillar that Yogi has embraced and promoted throughout his tenure. His leadership has taken Hindutva ideals directly to the people, consolidating Hindu votes and neutralizing the opposition's political strategies. This victory is also a direct response to critics who had suggested that his grip on the state was weakening. The by-election results have firmly established Yogi as the undisputed leader in Uttar Pradesh. Kundarki Constituency One of the most significant upsets occurred in Kundarki constituency, a region where the Muslim community makes up nearly 60% of the electorate. In previous elections, the Samajwadi Party (SP) had consistently won this seat, with Muslim candidates dominating the field. However, this time, despite 11 Muslim candidates standing in the race, BJP's Ramveer Singh clinched the seat with a massive margin of nearly one lakh votes. Yogi Adityanath had held two major rallies here, and his efforts proved decisive in flipping the results in BJP’s favor. Ambedkarnagar’s Katthehari Seat The Katthehari seat in Ambedkarnagar, previously won by Samajwadi Party’s Lalji Verma, also witnessed a significant change. Lalji Verma’s wife, Shobhavati Verma, was given the ticket this time, but BJP's Dharmaraj Nishad emerged victorious. Chief Minister Yogi Adityanath campaigned here three times, and his efforts once again proved instrumental in delivering a crucial win for the BJP. Meerapur Constituency In the Meerapur constituency, the election witnessed a dramatic and controversial situation. During the voting process, allegations surfaced that police used their uniforms and firearms to intimidate Muslim voters, preventing them from casting their ballots. However, counter-videos emerged, showing how police officers were pelted with stones by locals, turning the narrative around. Despite the controversy, the results saw the BJP-backed National Lok Dal (NLD) candidate Mithilesh Pal emerging victorious, defeating Samajwadi Party's prominent candidate, Sumbul Rana. Meerapur, which has nearly 40% Muslim voters, posed a significant challenge for the BJP, but once again, Yogi Adityanath’s strategic campaigning made the difference. Hindutva Agenda: The Key to BJP's Success The results from these constituencies clearly illustrate that the Hindutva agenda, led by Yogi Adityanath, played a central role in BJP's victory. In all three key seats—Kundarki, Katthehari, and Meerapur—the Hindu vote consolidation, backed by Yogi’s leadership and campaigning, was critical. The BJP’s ability to win even in Muslim-majority areas is a testament to how effectively the party's ideological message has resonated with the electorate. The results of the Uttar Pradesh by-elections have not only bolstered Yogi Adityanath’s political stature but have also reasserted the strength of the BJP in the state Stay informed on all the latest news , real-time breaking news updates, and follow all the important headlines in india news and world News on Zee News.
Appalachian St. 34, James Madison 20
Homeland Security shares new details of mysterious drone flights over New Jersey
By HALELUYA HADERO, Associated Press President-elect Donald Trump asked the Supreme Court on Friday to pause the potential TikTok ban from going into effect until his administration can pursue a “political resolution” to the issue. The request came as TikTok and the Biden administration filed opposing briefs to the court, in which the company argued the court should strike down a law that could ban the platform by Jan. 19 while the government emphasized its position that the statute is needed to eliminate a national security risk. “President Trump takes no position on the underlying merits of this dispute. Instead, he respectfully requests that the Court consider staying the Act’s deadline for divestment of January 19, 2025, while it considers the merits of this case,” said Trump’s amicus brief, which supported neither party in the case. The filings come ahead of oral arguments scheduled for Jan. 10 on whether the law, which requires TikTok to divest from its China-based parent company or face a ban, unlawfully restricts speech in violation of the First Amendment. Earlier this month, a panel of three federal judges on the U.S. Court of Appeals for the District of Columbia Circuit unanimously upheld the statute , leading TikTok to appeal the case to the Supreme Court. The brief from Trump said he opposes banning TikTok at this junction and “seeks the ability to resolve the issues at hand through political means once he takes office.”
Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Financial Highlights "In fiscal year 2024 we drove tremendous progress in our pipeline. It was a transformative year, marked by our first FDA approval and significant clinical milestones. The approval of LYMPHIRTM and the positive Phase 3 results for Mino-Lok® underscore our commitment to developing innovative therapies. Our team successfully responded to FDA comments related to the biologics license application for LYMPHIR and ultimately gained FDA approval. Productive engagement with the FDA regarding the positive results of our Phase 3 Mino-Lok® trial and Phase 2 Halo-Lido trial clarified our next steps for both programs. We anticipate continued engagement with the agency in the coming year and look forward to their guidance. Additionally, we are exploring strategic partnerships and licensing opportunities to maximize the potential of our portfolio and bring these important therapies to market efficiently," stated Leonard Mazur , Chairman and CEO of Citius Pharma. "Looking ahead, our priorities for fiscal year 2025 include launching LYMPHIRTM through our majority-owned subsidiary, Citius Oncology, driving the clinical and regulatory strategies for Mino-Lok® and Halo-Lido, fortifying our financial position, and applying a disciplined approach to resource allocation. We expect to launch LYMPHIR in the first half of 2025 and distribute CTOR shares to Citius Pharma shareholders by the end of the year, pending favorable market conditions. Our goal remains to deliver value for patients, healthcare providers, and shareholders. With a clear vision and a strong team, we are well-positioned to execute on our mission of bringing innovative therapies to market," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Liquidity As of September 30, 2024 , the Company had $3.3 million in cash and cash equivalents. As of September 30, 2024 , the Company had 7,247,243 common shares outstanding, as adjusted for the 1-for-25 reverse stock split of the Company's common stock, effected on November 25, 2024 . During the year ended September 30, 2024 , the Company received net proceeds of $13.8 million from the issuance of equity. The Company expects to raise additional capital to support operations. Research and Development (R&D) Expenses R&D expenses were $11.9 million for the full year ended September 30, 2024 , compared to $14.8 million for the full year ended September 30, 2023 . The decrease in R&D expenses primarily reflects the completion of the Halo-Lido trial and completion of activities related to the regulatory resubmission for LYMPHIR, offset by shutdown costs associated with the end of the Phase 3 trial for Mino-Lok. We expect research and development expenses to decrease in fiscal year 2025 as we continue to focus on the commercialization of LYMPHIR through our majority-owned subsidiary, Citius Oncology and because we have completed the Phase 3 trial for Mino-Lok. General and Administrative (G&A) Expenses G&A expenses were $18.2 million for the full year ended September 30, 2024 , compared to $15.3 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-launch and market research activities associated with LYMPHIR. General and administrative expenses consist primarily of compensation costs, professional fees for legal, regulatory, accounting and corporate development services, and investor relations expenses. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $11.8 million as compared to $6.6 million for the prior year. The increase of $5.2 million is largely due to the grant of options under the Citius Oncology stock plan. Stock-based compensation expense under the Citius Oncology stock plan was $7.5 million during the year ended September 30, 2024 , compared to $2.0 million for the year ended September 30, 2023 , as the plan was initiated in July 2023 . For the years ended September 30, 2024 and 2023, stock-based compensation expense also includes $47,547 and $130,382 , respectively, for the NoveCite stock option plan. In fiscal years 2023 and 2024, we granted options to our new employees and additional options to other employees, our directors, and consultants. Net loss Net loss was $39.4 million , or ($5.97) per share for the year ended September 30, 2024 , compared to a net loss of $32.5 million , or ($5.57) per share for the year ended September 30, 2023 , as adjusted for the reverse stock split. The increase in net loss reflects an increase in operating expense of $5.3 million offset by a decrease of $1.6 million in other income. Operating expense increased due to increases in stock-based compensation and general and administrative expenses, which were offset by decreased research and development expense. About Citius Pharmaceuticals, Inc. Citius Pharma is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024 , the FDA approved LYMPHIRTM, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com . Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR through our majority-owned subisity and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks related to research using our assets but conducted by third parties; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our ability to maintain compliance with Nasdaq's continued listing standards; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Pharma's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS PHARMACEUTICALS, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 ASSETS Current Assets: Cash and cash equivalents $ 3,251,880 $ 26,480,928 Inventory 8,268,766 — Prepaid expenses 2,700,000 7,889,506 Total Current Assets 14,220,646 34,370,434 Property and equipment, net — 1,432 Operating lease right-of-use asset, net 246,247 454,426 Other Assets: Deposits 38,062 38,062 In-process research and development 92,800,000 59,400,000 Goodwill 9,346,796 9,346,796 Total Other Assets 102,184,858 68,784,858 Total Assets $ 116,651,751 $ 103,611,150 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 4,927,211 $ 2,927,334 License payable 28,400,000 — Accrued expenses 17,027 476,300 Accrued compensation 2,229,018 2,156,983 Operating lease liability 241,547 218,380 Total Current Liabilities 35,814,803 5,778,997 Deferred tax liability 6,713,800 6,137,800 Operating lease liability – non current 21,318 262,865 Total Liabilities 42,549,921 12,179,662 Commitments and Contingencies Stockholders' Equity: Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding — — Common stock - $0.001 par value; 16,000,000 shares authorized; 7,247,243 and 6,354,371 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,247 6,354 Additional paid-in capital 271,440,421 253,056,133 Accumulated deficit (201,370,218) (162,231,379) Total Citius Pharmaceuticals, Inc. Stockholders' Equity 70,077,450 90,831,108 Non-controlling interest 4,024,380 600,380 Total Equity 74,101,830 91,431,488 Total Liabilities and Equity $ 116,651,751 $ 103,611,150 Reflects a 1-for-25 reverse stock split effective November 25, 2024. CITIUS PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 11,906,601 14,819,729 General and administrative 18,249,402 15,295,584 Stock-based compensation – general and administrative 11,839,678 6,616,705 Total Operating Expenses 41,995,681 36,732,018 Operating Loss (41,995,681) (36,732,018) Other Income: Interest income, net 758,000 1,179,417 Gain on sale of New Jersey net operating losses 2,387,842 3,585,689 Total Other Income Net 3,145,842 4,765,106 Loss before Income Taxes (38,849,839) (31,966,912) Income tax expense 576,000 576,000 Net Loss (39,425,839) (32,542,912) Net loss attributable to non-controlling interest 287,000 - Deemed dividend on warrant extension (1,047,312) (1,151,208) Net Loss Applicable to Common Stockholders $ (40,186,151) (33,694,120) Net Loss Per Share Applicable to Common Stockholders - Basic and Diluted $ (5.97) (5.57) Weighted Average Common Shares Outstanding
NEW YORK , Nov. 21, 2024 /PRNewswire/ -- BGC Group, Inc. (Nasdaq: BGC) ("BGC") Chairman and Chief Executive Officer Howard W. Lutnick provided the following statement: "I am deeply honored to have been nominated by President Donald J. Trump to serve as the 41st U.S. Secretary of Commerce. I look forward to this new chapter in my life, working for President Trump to promote economic growth, drive innovation, and strengthen our nation's financial security. Upon U.S. Senate confirmation, I will step down from my positions at Cantor, BGC, and Newmark. I intend to divest my interests in these companies to comply with U.S. government ethics rules and do not expect any arrangement which involves selling shares on the open market. I have full confidence in my exceptional management team at BGC. I have met with the Board of Directors and informed them that I expect to recommend that John Abularrage , Jean-Pierre Aubin , and Sean Windeatt be named Co-CEOs of BGC effective upon my confirmation. I am certain they will continue to drive our success, upholding the best interests of our clients, investors, and employees." BGC expects no changes to its existing corporate structure and expects to disclose further details at a later date. About BGC Group, Inc. BGC Group, Inc. (Nasdaq: BGC) is a leading global marketplace, data, and financial technology services company for a broad range of products, including fixed income, foreign exchange, energy, commodities, shipping, equities, and now includes the FMX Futures Exchange. BGC's clients are many of the world's largest banks, broker-dealers, investment banks, trading firms, hedge funds, governments, corporations, and investment firms. BGC and leading global investment banks and market making firms have partnered to create FMX, part of the BGC Group of companies, which includes a U.S. interest rate futures exchange, spot foreign exchange platform and the world's fastest growing U.S. cash treasuries platform. For more information about BGC, please visit www.bgcg.com . Discussion of Forward-Looking Statements about BGC Statements in this document regarding BGC that are not historical facts are "forward-looking statements" that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company's business, results, financial position, liquidity and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, BGC undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see BGC's Securities and Exchange Commission ("SEC") filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K. View original content to download multimedia: https://www.prnewswire.com/news-releases/bgcs-howard-w-lutnick-nominated-for-us-secretary-of-commerce-302313558.html SOURCE BGC Group, Inc.
Semrush Holdings, Inc. ( NASDAQ:SEMR – Get Free Report ) Director Dmitry Melnikov sold 16,467 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.26, for a total value of $201,885.42. Following the completion of the transaction, the director now owns 8,841,297 shares of the company’s stock, valued at $108,394,301.22. This trade represents a 0.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink . Dmitry Melnikov also recently made the following trade(s): Semrush Trading Down 2.9 % SEMR stock opened at $11.97 on Friday. Semrush Holdings, Inc. has a 12 month low of $9.64 and a 12 month high of $16.42. The stock has a market capitalization of $1.76 billion, a P/E ratio of 149.64 and a beta of 1.59. The firm has a 50-day moving average price of $13.40 and a 200-day moving average price of $13.69. Institutional Inflows and Outflows Analysts Set New Price Targets Several research analysts have issued reports on the company. JPMorgan Chase & Co. upped their price target on Semrush from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Wednesday, October 2nd. The Goldman Sachs Group raised their target price on Semrush from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Monday, October 7th. KeyCorp lifted their price target on Semrush from $19.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 2nd. Finally, Needham & Company LLC restated a “buy” rating and set a $18.00 price target on shares of Semrush in a research note on Monday, November 11th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $16.50. Get Our Latest Report on SEMR About Semrush ( Get Free Report ) Semrush Holdings, Inc develops an online visibility management software-as-a-service platform in the United States, the United Kingdom, and internationally. The company enables companies to identify and reach the right audience for their content through the right channels. Its platform enables the company's customers to understand trends and act upon insights to enhance the online visibility, and drive traffic to their websites and social media pages, as well as online listings, distribute targeted content to their customers, and measure the digital marketing campaigns. Further Reading Receive News & Ratings for Semrush Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semrush and related companies with MarketBeat.com's FREE daily email newsletter .SoFi Technologies, Inc. ( NASDAQ:SOFI – Get Free Report )’s stock price was up 2.2% during mid-day trading on Thursday . The stock traded as high as $16.44 and last traded at $16.38. Approximately 8,949,219 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 47,423,371 shares. The stock had previously closed at $16.02. Analyst Upgrades and Downgrades SOFI has been the topic of a number of research analyst reports. Bank of America reissued an “underperform” rating and issued a $12.00 target price on shares of SoFi Technologies in a research note on Monday, December 9th. Morgan Stanley raised their price objective on SoFi Technologies from $7.50 to $13.00 and gave the company an “underweight” rating in a report on Thursday, December 19th. JPMorgan Chase & Co. boosted their target price on SoFi Technologies from $9.00 to $16.00 and gave the stock a “neutral” rating in a research report on Monday, December 2nd. Needham & Company LLC increased their price target on shares of SoFi Technologies from $10.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Finally, Mizuho boosted their price objective on shares of SoFi Technologies from $14.00 to $16.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $11.04. Check Out Our Latest Stock Analysis on SOFI SoFi Technologies Price Performance SoFi Technologies ( NASDAQ:SOFI – Get Free Report ) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.01. SoFi Technologies had a return on equity of 3.71% and a net margin of 8.38%. The company had revenue of $697.10 million for the quarter, compared to the consensus estimate of $631.59 million. During the same quarter in the previous year, the business earned ($0.03) EPS. SoFi Technologies’s revenue was up 29.8% compared to the same quarter last year. On average, research analysts expect that SoFi Technologies, Inc. will post 0.12 EPS for the current fiscal year. Insider Activity at SoFi Technologies In related news, CTO Jeremy Rishel sold 64,991 shares of SoFi Technologies stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $15.72, for a total transaction of $1,021,658.52. Following the sale, the chief technology officer now directly owns 586,494 shares in the company, valued at $9,219,685.68. The trade was a 9.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink . Also, EVP Kelli Keough sold 9,590 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $14.56, for a total value of $139,630.40. Following the completion of the sale, the executive vice president now directly owns 142,613 shares in the company, valued at approximately $2,076,445.28. The trade was a 6.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders have sold a total of 26,009,264 shares of company stock worth $416,889,795 over the last quarter. Corporate insiders own 2.60% of the company’s stock. Institutional Trading of SoFi Technologies Hedge funds and other institutional investors have recently modified their holdings of the business. World Investment Advisors LLC lifted its position in SoFi Technologies by 6.5% during the 3rd quarter. World Investment Advisors LLC now owns 21,745 shares of the company’s stock valued at $171,000 after acquiring an additional 1,336 shares during the period. Virtu Financial LLC purchased a new position in shares of SoFi Technologies during the third quarter valued at approximately $1,649,000. Coldstream Capital Management Inc. bought a new stake in shares of SoFi Technologies in the 3rd quarter worth approximately $93,000. Geode Capital Management LLC grew its stake in shares of SoFi Technologies by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 17,619,084 shares of the company’s stock worth $138,523,000 after buying an additional 358,806 shares during the last quarter. Finally, M&T Bank Corp raised its stake in SoFi Technologies by 5.4% during the third quarter. M&T Bank Corp now owns 45,582 shares of the company’s stock valued at $359,000 after buying an additional 2,332 shares during the last quarter. 38.43% of the stock is owned by hedge funds and other institutional investors. About SoFi Technologies ( Get Free Report ) SoFi Technologies, Inc provides various financial services in the United States, Latin America, and Canada. It operates through three segments: Lending, Technology Platform, and Financial Services. The company offers lending and financial services and products that allows its members to borrow, save, spend, invest, and protect money. Featured Articles Receive News & Ratings for SoFi Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SoFi Technologies and related companies with MarketBeat.com's FREE daily email newsletter .Trump opposes TikTok ban, asks Supreme Court for time to resolve via negotiations